A phase ii clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2335-2341

  Strosberg, J R ^a   Weber, J M ^a   Choi, J ^a   Campos, T L ^a   Valone, T L ^a   Han, G ^a   Schell, M J ^a   Kvols, L K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Hepatic TAE; NET; Sunitinib; VEGF

Indexed keywords

SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ARTIFICIAL EMBOLISM; BACKACHE; BLOOD TOXICITY; CANCER FATIGUE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; EPISTAXIS; FEMALE; FEVER; HAIR LOSS; HAND FOOT SYNDROME; HEMORRHOID; HUMAN; HYPERPIGMENTATION; HYPERTENSION; LIVER METASTASIS; LUNG DISEASE; MALE; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHINITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; TASTE DISORDER; THERAPY EFFECT; WEIGHT REDUCTION;

ACRYLIC RESINS; ADULT; AGED; ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; GELATIN; HEPATIC ARTERY; HUMANS; INDOLES; INTESTINAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PROPORTIONAL HAZARDS MODELS; PYRROLES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865573372     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr614     Document Type: Article

References (30)

1. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5(10): 1502-1522.
2. Strosberg JR, Nasir A, Hodul P, Kvols L Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2008; 2(3): 113-125.
3. Norheim I, Oberg K, Theodorsson-Norheim E et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206(2): 115-125.
4. Strosberg J, Gardner N, Kvols L Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89 (4): 471-476.
5. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197(1): 29-37.
6. Norton JA, Warren RS, Kelly MG et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134(6): 1057-1063; discussion 1063-1055.
7. McEntee GP, Nagorney DM, Kvols LK et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108(6): 1091-1096.
8. Que FG, Nagorney DM, Batts KP et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169(1): 36-42. discussion 42-33.
9. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004; 80(Suppl 1): 74-78.
10. Kvols LK, Turaga KK, Strosberg J, Choi J Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw 2009; 7(7): 765-772.
11. Hellman P, Ladjevardi S, Skogseid B et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002; 26(8): 1052-1056.
12. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315(11): 663-666.
13. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15(6): 966-973.
14. Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27(28): 4656-4663.
15. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6): 514-523.
16. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6): 501-513.
17. Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 2001; 25(6): 685-688.
18. Gupta S, Yao JC, Ahrar K et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9(4): 261-267.
19. Eriksson BK, Larsson EG, Skogseid BM et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83(11): 2293-2301.
20. Strosberg JR, Choi J, Cantor AB, Kvols LK Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13(1): 72-78.
21. Ruszniewski P, Rougier P, Roche A et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71(8): 2624-2630.
22. Loewe C, Schindl M, Cejna M et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol:assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180(5): 1379-1384.
23. Therasse E, Breittmayer F, Roche A et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189(2): 541-547.
24. Bloomston M, Al-Saif O, Klemanski D et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 2007; 11(3): 264-271.
25. Li X, Feng GS, Zheng CS et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10(19): 2878-2882.
26. Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32(2): 133-138.
27. Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26(8): 1316-1323.
28. Hansel DE, Rahman A, Hermans J et al. Liver metastases arising from welldifferentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003; 16(7): 652-659.
29. Faivre S, Demetri G, Sargent W, Raymond E Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6(9): 734-745.
30. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327-337.